Company intelligence / Profile preview

KAI Capital

South San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

KAI developed selective modulators of protein kinase C for cardiovascular, renal, and pain indications. Lead program KAI‑4169 showed compelling Phase IIa results for secondary hyperparathyroidism in CKD patients on dialysis and was acquired by Amgen for further development. The compound was later approved as etelcalcetide. Other pipeline assets were preclinical or early clinical.

Therapeutic areas: NeurologyCardiovascularNephrology
Modalities: Small moleculeSynthetic peptidePeptide
Industry: Biotech

Partnerships

Ono Pharmaceutical Co., Ltd. – partnership to develop/commercialize etelcalcetide/Kai–4169 in Japan.

Beyond the preview

Go deeper on KAI Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KAI Capital.

Explore the full profile